Meropenem: Current perspective

Vishnu Kumar Goyal, Satendra Singh Rajput

Abstract


Meropenem is an ultra broad spectrum parenteral carbapenem with excellent safety profile and minimal drug interactions. It is effective in a variety of tissue infections. But to prevent emerging drug resistance, its use should be restricted to complicated/serious infections not amenable to other antimicrobials .

Key Words

Carbapenem, meropenem, drug resistant enterobacteriaceae (DRE).


Full Text:

PDF

References


Craig WA. The Pharmacology of Meropenem: A New Carbapenem Antibiotic. Clinical Infectious Diseases 1997; 24(Suppl 2):S266-75.

Lowe MN, Lamb HM. Meropenem: An Updated Review of its Use in the Management of IntraAbdominal Infections. Drugs 2000 Sep; 60(3):619-646.

Nicolau DP. Pharmacokinetic and Pharmacodynamic Properties of Meropenem. Clinical Infectious Diseases 2008; 47:S32–40.

Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present and future. Antimicrob Agents Chemother Nov 2011; 55(11): 4943–4960.

Shah D, Narang M. Meropenem: Drug therapy. Indian paediatrics 2004 May; 42:443-45

Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006 July;124: 95-98.

Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, RousselDelvallez M. Comparative invitro activity of meropenem, imipenem and piperacillin/tazoabctam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010; 10:72.

Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials. Diagn Microbiol Inect Dis. 2003 Sep;47(1):365-72.

Mohr JF. Update on the Efficacy and Tolerability of Meropenem in the Treatment of Serious Bacterial Infections. Clin Infect Dis. 2008; 47: S41-S51.

Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68(6):803-38.

Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999;31(1):3-10.

Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drugs Saf 2007;30(8):657-68.

Cunha BA, Hamid NS, Krol V, Eisentein L. Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. J Chemother 2008 Apr;20(2):233-7.

Ferrara A, Grassi G, Grassi FA, Piccioni PD, Gialdroni Grassi G. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989 Sep;24 Suppl A:239-50.

Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007;39(4):647-57.

Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011 Sep;30(9):812-3.

Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989 Sep;24 (Suppl A):311-20.


Refbacks

  • There are currently no refbacks.


Copyright © 2014 International Journal of Medical Science Research and Practice. All rights reserved. Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.